![Regulus Therapeutics](https://storage.googleapis.com/dealroom-images-production/9f/MTAwOjEwMDpjb21wYW55QHMzLWV1LXdlc3QtMS5hbWF6b25hd3MuY29tL2RlYWxyb29tLWltYWdlcy8yMDI0LzA4LzIzLzk3MzMyMmNmZmQwYmI0Zjk2YTJjZGJhZjM5YmRjODU2.png)
Regulus Therapeutics
Regulus Therapeutics – A Leading microRNA Therapeutics Company | Regulus Therapeutics – a leading company developing microRNA therapeutics. Medicines that target the pathways of human disease..
Launch date
Employees
Market cap
€95.8m
Enterprise valuation
€11m (Public information from Sep 2024)
Share price
$1.71 RGLS
San Diego California (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 10.0m | - | - | - | - | - | - |
% growth | 46 % | - | - | - | - | - | - |
EBITDA | (14.2m) | (27.8m) | (28.2m) | (29.2m) | (45.8m) | (54.7m) | - |
% EBITDA margin | (141 %) | - | - | - | - | - | - |
Profit | (15.7m) | (27.8m) | (28.3m) | (30.0m) | (41.8m) | (66.5m) | (91.0m) |
% profit margin | (157 %) | - | - | - | - | - | - |
EV / revenue | 6.4x | - | - | - | - | - | - |
EV / EBITDA | -4.5x | -1.6x | 0.0x | -0.2x | -0.7x | -1.5x | - |
R&D budget | 15.3m | 17.8m | 18.4m | 21.2m | - | - | - |
R&D % of revenue | 153 % | - | - | - | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $20.0m | Series A | |
$10.0m | Early VC | ||
N/A | $25.0m | Debt | |
N/A | $45.0m Valuation: $137m | IPO | |
* | N/A | $49.2m | Post IPO Equity |
N/A | $10.0m | Post IPO Equity | |
N/A | $104m | Post IPO Equity | |
$30.0m | Debt | ||
N/A | - | ||
* | N/A | $43.0m | Post IPO Equity |
N/A | $16.7m | Post IPO Equity | |
N/A | $19.4m | Private Placement VC | |
* | N/A | $34.6m | Private Placement VC |
* | $15.0m | Post IPO Equity | |
* | $100m | Private Placement VC | |
Total Funding | €167m |
Recent News about Regulus Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.